Showing 711-720 of 791 results for "".
- Gene Variants May Drive Persistent Lesions in Darier Diseasehttps://practicaldermatology.com/news/gene-variants-may-drive-persistent-lesions-darier-disease/2462509/Persistent lesions in patients with Darier disease were associated with second-hit variants in the ATP2A2 gene, according to data from a new case series of 9 patients. In a study published in JAMA Dermatology, Lihi Atzmony, MD, of Rabin Medical Center, Petach Tikva, Israel, and c
- AI In Action: Almirall, Absci AI Drug Discovery Partner to Rapidly Develop New treatments for Skin Diseaseshttps://practicaldermatology.com/news/ai-in-action-almirall-absci-ai-drug-discovery-partner-to-rapidly-develop-new-treatments-for-skin-diseases/2462135/Almirall S.A. and Absci Corporation, a generative artificial intelligence (AI) drug creation company, are teaming up to develop and commercialize AI-designed therapeutics to treat dermatological diseases. The partnership combines Absci’s Integrated Drug C
- Exploring OX40’s Role in AD: A Conversation With Dr. Stephan Weidingerhttps://practicaldermatology.com/news/exploring-ox40s-role-in-ad-a-conversation-with-dr-stephan-weidinger/2462078/The anti-Ox40-ligand antibody amlitelimab performed well in the phase 2b Stream-AD trial of adults with moderate-to-severe atopic dermatitis, according to research presented at the European Academy of Dermatology and Venereology (EADV) Congress 2023 in Berlin. Amlitelimab demonstrated c
- Breaking Business News: Lilly to Acquire DICE Therapeuticshttps://practicaldermatology.com/news/breaking-business-news-lilly-to-acquire-dice-therapeutics/2461796/Eli Lilly and Company will acquire DICE Therapeutics, Inc. for a cool $2.4 billion to expand its immunology pipeline. DICE Therapeutics, Inc. is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic c
- Arctiva Eczema Cream Spells Relief for 91% of Patientshttps://practicaldermatology.com/news/study-arctiva-eczema-cream-spells-relief-for-91-of-patients/2461688/Fully 91% of participants reported improvement in eczema irritation using proprietary Arctiva Eczema Cream, a new study shows. Arctiva Eczema Cream features Hydrosurf glycolipid technology—a blend of fermented ingredients with origins from Antarctica. It is combined with 1% C
- MTX Use May Up Risk for Three Types of Skin Cancerhttps://practicaldermatology.com/news/mtx-use-may-up-skin-cancer-risk/2461546/Methotrexate (MTX) may increase risk for three types of skin cancer, according to a new study out of University of Gothenburg. Patients receiving the drug include those with moderate to severe psoriasis; but in this particular patient group, a risk increase was only observed for basal c
- EADV News: Tape Strip Test May Predict Eczema Risk in Babieshttps://practicaldermatology.com/news/eadv-news-tape-strip-test-may-predict-eczema-risk-in-babies/2461329/An immune biomarker in newborns may predict the subsequent onset and severity of paediatric atopic eczema, according to a new study presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress. The Barrier dysfunction in Atopic newBorns (BABY) study analyzed a c
- FDA Cracks Down on Three Companies for Selling Unapproved New Drugs for Mole and Skin Tag Removalhttps://practicaldermatology.com/news/fda-cracks-down-on-three-companies-for-selling-unapproved-new-drugs-for-mole-and-skin-tag-removal/2461294/The U.S. Food and Drug Administration issued three warning letters to three companies, including Amazon, for selling unapproved products for removing moles and skin tags, in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). There are no FDA-appr
- DermTech Appoints Two New Board Membershttps://practicaldermatology.com/news/dermtech-appoints-two-new-board-members/2461272/DermTech, Inc. appointed Kirk D. Malloy, Ph.D. and Mark C. Capone, M.S. to the Company’s board of directors, effective July 18,2022. These appointments expand DermTech’s board of directors to eight members. “We are excited to welco
- Cutera Hosts AviClear Webinar This Weekhttps://practicaldermatology.com/news/cutera-hosts-aviclear-webinar-this-week/2461178/Cutera hosts the first webinar for AviClear, the first and only FDA cleared energy-based device for the treatment of mild, moderate, and severe acne, this week. Dermatologists Jeffrey S. Dover, MD, FRCPC and Julie C. Harper, MD will discuss the latest advancement in the treatment of acn